Based on these results (Figure 2), the MORPHEUS clinical trials were started including treatment arms combining immune-checkpoint inhibitors with CXCR4 inhibition (NCT03193190, NCT03281369 and NCT03337698 for pancreatic cancer, gastric cancer and non-small cell lung cancer, respectively). This evidence concerns the gene CXCR4 and non-small cell lung carcinoma.